Ptc Therapeutics (PTCT) Short term Debt (2012 - 2026)

Ptc Therapeutics' Short term Debt history runs 12 years deep, the most recent figure standing at $314.2 million for Q2 2026.

• In Q2 2026, Short term Debt rose 19.92% year-over-year to $314.2 million; the TTM figure through Jun 2026 stood at $314.2 million (up 19.92% YoY), while the FY2025 annual figure was $286.6 million, up 11.17% from the prior year.
• Short term Debt for Q2 2026 stood at $314.2 million, up from $305.0 million in the prior quarter.
• The five-year high for Short term Debt was $314.2 million in Q2 2026, with the low at $72.1 million in Q4 2022.
• The 5-year median for Short term Debt is $237.7 million (2024), against an average of $203.0 million.
• Peak annual rise in Short term Debt reached 351.66% in 2022, while the deepest fall reached 51.75% in 2022.
• Ptc Therapeutics' Short term Debt stood at $72.1 million in 2022, then jumped by 169.32% to $194.3 million in 2023, then soared by 32.68% to $257.8 million in 2024, then advanced by 11.17% to $286.6 million in 2025, then advanced by 9.62% to $314.2 million in 2026.
• Business Quant data shows PTCT's Short term Debt at $314.2 million in Q2 2026, $305.0 million in Q1 2026, and $286.6 million in Q4 2025.